Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia

Full text
Author(s):
Lucena-Araujo, Antonio R. [1] ; de Oliveira, Fabio Morato [1] ; Leite-Cueva, Sabrina Dias [2] ; dos Santos, Guilherme Augusto [1] ; Falcao, Roberto Passeto [1] ; Rego, Eduardo Magalhaes [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Med Sch Ribeirao Preto, Natl Inst Sci & Technol Cell Based Therapy, Div Hematol, Dept Internal Med, BR-14048900 Ribeirao Preto - Brazil
[2] Univ Sao Paulo, Med Sch Ribeirao Preto, Natl Inst Sci & Technol Cell Based Therapy, Dept Genet, BR-14048900 Ribeirao Preto - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Leukemia Research; v. 35, n. 2, p. 260-264, FEB 2011.
Web of Science Citations: 36
Abstract

In the present study, we analyzed AURKA and AURKB gene expression in 70 acute myeloid leukemia (AML) patients. There was no difference between leukemic samples and bone marrow mononuclear cells (BMMCs, n = 8) or CD34(+) progenitors (n = 10) from healthy donors. High white blood cells (WBC) counts were observed in the AURKA(+) and AURKB(+) groups, but no significant differences regarding age, gender, platelet counts or frequency of FLT3-ITD mutations. AURKA, but not AURKB, expression was independently associated with high WBC counts (OR: 3.15, 95% CI 1.07-9.24, p = 0.03). Moreover, the majority of cases that overexpressed AURKA and AURKB presented unfavorable cytogenetic abnormalities (p < 0.001). In conclusion, we described a significant association between overexpression of AURKA/B and cytogenetics findings in AML, which may be relevant to new therapeutic approaches, based on Aurora kinase inhibitors. (C) 2010 Elsevier Ltd. All rights reserved. (AU)